Endovastec(SH:688016) Sou Hu Cai Jing·2025-12-30 11:38Group 1 - The core viewpoint of the article highlights the financial performance and stock movement of Xinmai Medical (688016) as of December 30, 2025, with a closing price of 91.6 yuan, reflecting a decline of 1.01% [1] - The company reported a main revenue of 1.015 billion yuan for the first three quarters of 2025, showing a year-on-year increase of 4.66%, while the net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2] - In Q3 2025, the company achieved a single-quarter main revenue of 300 million yuan, a significant year-on-year increase of 64.68%, but the net profit attributable to shareholders fell by 23.63% to 114 million yuan [2] Group 2 - The company has a debt ratio of 15.85% and reported investment income of 11.6 million yuan, with financial expenses recorded at -7.8584 million yuan, indicating a strong financial position [2] - The gross profit margin for Xinmai Medical stands at 70.4%, reflecting the company's efficiency in managing production costs [2] - Over the past 90 days, 7 institutions have provided ratings for the stock, with 6 buy ratings and 1 hold rating, and the average target price set by institutions is 136.03 yuan [2]